Analysis of uterine corporeal mesenchymal tumors occurring after menopause

BMC Womens Health. 2019 Jan 18;19(1):13. doi: 10.1186/s12905-019-0714-5.

Abstract

Objective: Because it is difficult to diagnose accurately whether uterine corporeal mesenchymal tumors are benign or malignant before surgery, an understanding of the characteristics of patients with uterine sarcomas occurring in the postmenopausal period is required.

Methods: We retrospectively reviewed the cases of women who underwent surgery for uterine mesenchymal tumors at our hospital.

Results: Among 487 operated cases, 447 tumors occurred in the premenopausal period and 40 occurred in the postmenopausal period. Uterine sarcomas were observed in 5 cases (1.1%) during the premenopausal period and in 11 cases (28%) during the postmenopausal period. Among the postmenopausal patients, age, age at menopause, body mass index (BMI), tumor size, incidence of abnormal vaginal bleeding, serum tumor marker levels (cancer antigen 125, carbohydrate antigen 19-9, and carcinoembryonic antigen), and serum lactate dehydrogenase values were not significantly different between patients with benign tumors and those with malignant tumors. On the other hand, the incidence to have abnormal signal on MRI was significantly higher in patients with malignant tumors than in patients with benign tumors.

Conclusion: In our hospital, the incidence of malignant tumors in women with uterine corporeal mesenchymal tumors was much higher in postmenopausal patients than in premenopausal patients. Because it is generally not easy to diagnose uterine sarcomas before surgery, surgery should be positively considered when uterine sarcomas cannot be ruled out for patients in the postmenopausal period.

Keywords: Leiomyoma, uterine; Leiomyosarcoma,uterine; Postmenopausal period.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood
  • Epithelial-Mesenchymal Transition*
  • Female
  • Humans
  • Incidence
  • Japan
  • Leiomyoma / diagnosis
  • Middle Aged
  • Postmenopause*
  • Retrospective Studies
  • Sarcoma / blood
  • Sarcoma / diagnosis*
  • Sarcoma / physiopathology
  • Uterine Neoplasms / blood
  • Uterine Neoplasms / diagnosis*
  • Uterine Neoplasms / physiopathology
  • Uterine Neoplasms / surgery

Substances

  • Biomarkers, Tumor